OXiGENE – About the Company
OXiGENE is a biopharmaceutical company developing vascular disrupting agents for patients with cancer. Lead candidate CA4P binds tubulin in endothelial cells to induce a conformational change, which restricts blood flow and starves tumors of nutrients. A pivotal Phase II/III trial with CA4P in patients with platinum-resistant ovarian cancer is expected to launch in the second quarter of 2016. Last year OXiGENE brought in a new management team, including industry and FDA veteran Bill Schwieterman, to unlock the value of CA4P and the Company’s pipeline of oncology candidates.